Read about upcoming changes to coverage.
Mismatch repair-deficient (dMMR) colon cancer, also known as microsatellite instability-high (MSI-H),听is a biologically distinct form of colorectal cancer听caused by mutations in some of the genes that are involved in correcting mistakes made when DNA is copied in a cell. This type of colon cancer is highly responsive to treatment with immunotherapy, which has听reshaped how听肠濒颈苍颈肠颈补苍蝉鈥听补辫辫谤辞补肠丑听肠补谤别,听leading to major advances across both early-stage and metastatic disease.听
Here, we take a closer look at what makes听dMMR听colon cancer different, why these tumors respond so well to therapies听that activate the听辫补迟颈别苍迟鈥檚听own immune system, known as immunotherapy, and how recent research is changing听how we approach patients with these tumors. From new first-line treatments for metastatic disease to promising approaches before surgery, these advances are听helping听many听patients with听colon cancer听live听longer听and feel听healthier, often听with fewer side effects than older chemotherapy-only strategies. Understanding the science behind听this听dMMR听colon cancer subtype听is helping听doctors听match the right treatment to the right patient at the right time.听
When cells divide, they must copy DNA accurately. The mismatch repair system acts as a molecular proofreader, correcting small errors that occur during听cell听replication. If this system fails, mutations accumulate throughout the genome.听These mutations are then听transcripted听to proteins that have mutations or alterations. When tumors听develop under these conditions, these听abnormal proteins, known as neoantigens,听are readily recognized by听the immune system as foreign. This heightened immune visibility explains why听dMMR听tumors often show听a听heavy immune cell infiltration and why they respond so well to听a type of immunotherapy known as听immune checkpoint inhibitors.听
Mismatch repair deficiency can occur听spontaneously in the body听or听due to other genetic conditions, such as听Lynch syndrome. Lynch syndrome is听an inherited condition听that is passed down in families and听results in听mutations听in these听mismatch repair genes, resulting听in听a听faulty proofreading system. Lynch syndrome affects roughly听one听in 280 Americans and听having听a mutation in one of these repair genes听increases the听overall听risk of developing听cancer听and at a younger age. People with Lynch syndrome听are听especially听at risk for developing colorectal and endometrial cancers.听听
Research has shown that approximately听12鈥15 percent of听all听colorectal cancers are听mismatch repair听deficient.听Whether the deficiency arises from Lynch syndrome or sporadic causes, immunotherapy responses are similarly strong because the underlying feature听of听the high mutation burden听remains the key driver听for these cancers.听
The prevalence of听dMMR听varies by stage. It is more common in early-stage colon cancer and less frequent in metastatic disease, suggesting that tumors capable of spreading may have developed mechanisms to evade immune control.听听
In stage II and some stage III听colon听cancers,听dMMR听status has historically been associated with a better prognosis.听These听grow more slowly and are recognized by the immune system more effectively.听Patients听with stage II听dMMR听colon cancer generally have lower rates of recurrence and improved overall survival compared with听stage II colon cancer without听dMMR.听听
That advantage appears to diminish with extensive lymph node involvement and is not seen once the disease becomes metastatic.听In metastatic colon cancer,听dMMR听tumors behave more aggressively. Historically,听outcomes听for this subset of patients听have been听similar to, or slightly worse than, mismatch repair鈥損roficient tumors when treated with chemotherapy alone.听This听resistance to standard cytotoxic regimens听has听likely contributed to poorer historical outcomes听for patients with metastatic mismatch repair deficient colon cancer. Advances in immunotherapy and听its听incorporation into treatment regimens is changing that.听听听
While initial surgical management is similar for all colon cancers,听dMMR听tumors have historically not responded as well to chemotherapy, such as FOLFOX or FOLFIRI,听compared with other types of colon cancer.听This limited听the听long-term听cancer听control options for these tumors until the introduction of immune checkpoint inhibitors. Checkpoint inhibitors are a form of immunotherapy that work by helping to lift the brakes off the immune cells (T cells) that are responsible for fighting cancer, allowing them to better recognize the cancer听cells听in the body.听听听
The most dramatic听treatment听advance听with immune checkpoint inhibitors听has occurred in metastatic听dMMR听colorectal cancer.听Multiple large clinical trials demonstrated that PD-1 inhibitors such as pembrolizumab听or nivolumab听produce higher response rates and more durable disease control than standard chemotherapy.听Patients receiving immunotherapy as their first treatment often experience fewer symptoms, delayed disease progression, and in many cases, an听improvement in overall quality of life.听These听clinical trial听results听have听established immunotherapy as the preferred first-line treatment for metastatic听dMMR听disease, largely replacing chemotherapy听for most patients with this subtype听of colon cancer.听听
Combination immunotherapy has further improved outcomes听for some patients. Regimens pairing PD-1 inhibitors with CTLA-4 inhibitors, such as nivolumab plus ipilimumab, have shown superior progression-free survival compared with single-agent immunotherapy or chemotherapy.听This approach aims to activate the immune system from multiple angles to generate a more powerful response.听
While dual therapy can increase immune-related side effects,听such as skin, liver, or gastrointestinal tract inflammation,听most are manageable with careful monitoring.听Because of this,听immunotherapy听treatment听selection is often individualized, with combination therapy favored for younger, fitter patients or those with bulky disease, and single-agent therapy chosen for older or more frail individuals.听
As ongoing听research听studies听help to further听refine these strategies, immunotherapy continues to reshape the outlook for听patients with听metastatic听dMMR听colorectal cancer. What was once a听very听difficult听to听treat听form of colon cancer听now has more听treatment听options available.听
The success of immunotherapy for metastatic听dMMR听colon cancer听has led to research听evaluating听these treatments in earlier stages听of the disease.听For years, stage III colon cancer was treated with six months of adjuvant chemotherapy听following surgery, which was听determined to听not听be听as effective in听dMMR听tumors.听鈥Building on the advances of using immunotherapy to treat stage听four听dMMR听colon cancer, investigators contemplated the use of immunotherapy听earlier on, in patients with听stage III听dMMR听colon cancer,鈥 explains Dr. Shah.听听听
A recent study听showed听that adding immunotherapy to chemotherapy for stage III听dMMR听colorectal听tumors significantly reduces听risk of听recurrence, leading to听significant听updates in treatment guidelines and integration听of听immune-based approaches earlier in the disease course.听These findings have听changed the way听physicians听approach听caring for patients with听stage III听dMMR听colon cancer, and听these research results听have听opened the door to听using听immunotherapy in听those with听high-risk stage II听colon cancer听as well.听
The role of neoadjuvant immunotherapy,听giving the immunotherapy听treatment听before surgery,听is another promising strategy.听Treating earlier-stage听dMMR听tumors before surgery has the advantage of听leveraging the听intact tumor tissue to听try to听help stimulate a stronger immune response.听Early trials have reported remarkably high rates of tumor regression after just a few doses of immune checkpoint inhibitors, with many patients achieving complete pathologic response. These results raise the possibility that some individuals may eventually require less extensive surgery听or shorter courses of postoperative therapy.听There may even be potential for some patients to avoid surgery entirely.听
Despite听the听success听and promise, not all听dMMR听tumors respond to immunotherapy, and some听patients听eventually develop听treatment听resistance. Research suggests that听this 鈥immune escape鈥听can occur through disruptions in antigen presentation, alterations in T-cell receptor signaling and changes in interferon pathways.听听
Because听dMMR听tumors share certain recurrent mutations, investigators are exploring vaccine-based approaches听for early-stage disease and those at increased risk for developing these cancers due to Lynch syndrome. This vaccine approach may help听stimulate听the immune system to听recognize and听kill听the cancer听early, as well as听prevent cancers from forming in the first place. These strategies听aim to听balance potential benefit with the risk of immune-related side effects.听
Since Lynch syndrome increases a person鈥檚 risk of multiple cancers over a lifetime, immunotherapy is now being explored not just as a treatment strategy,听but also as a potential preventive tool in high鈥risk individuals. For families affected by Lynch syndrome, genetic counseling, coordinated surveillance, and emerging prevention strategies form a comprehensive approach that supports both patients and at鈥risk relatives.听
Dr. Shah highlights that 鈥渢he future of听dMMR听colon cancer care is moving towards听more precise and less toxic treatment, which is a real benefit that patients truly appreciate.鈥澨Researchers are studying novel drug combinations, targeted therapies such as synthetic lethal approaches and cellular therapies. Circulating tumor DNA and immune monitoring may help determine which patients can safely stop treatment and which need longer therapy to prevent听disease听relapse.听
What is clear is that understanding the biology of mismatch repair deficiency has听transformed听care. Immunotherapy has shifted the paradigm from conventional chemotherapy to immunotherapy-based strategies that offer longer survival and, in some cases, the potential for cure. As research continues,听treatment is expected to become even more personalized, aiming to maximize effectiveness while minimizing the burden of therapy.听
To hear a more in-depth discussion about this topic, tune in to the听CancerCast听podcast where host听Dr. Manish Shah听speaks with two experts to discuss mismatch repair deficient colon cancer and how this subset of colon cancer is managed and treated differently. Listen on听,听,听, or the听.听
